Sientra Inc (NASDAQ:SIEN) has received a consensus recommendation of “Hold” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $14.00.
A number of brokerages have weighed in on SIEN. BidaskClub raised Sientra from a “sell” rating to a “hold” rating in a research report on Friday, December 15th. Zacks Investment Research raised Sientra from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine downgraded Sientra from a “hold” rating to a “sell” rating in a research report on Thursday, February 22nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $19.00 target price on shares of Sientra in a research report on Friday, January 5th. Finally, William Blair reaffirmed a “buy” rating on shares of Sientra in a research report on Thursday, March 1st.
Shares of Sientra (SIEN) traded up $0.20 during midday trading on Wednesday, reaching $10.31. The company’s stock had a trading volume of 112,684 shares, compared to its average volume of 264,953. The firm has a market capitalization of $196.15, a P/E ratio of -3.62 and a beta of -1.10. The company has a current ratio of 2.87, a quick ratio of 1.92 and a debt-to-equity ratio of 0.57. Sientra has a 1 year low of $7.20 and a 1 year high of $16.68.
Institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors grew its position in shares of Sientra by 260.4% in the second quarter. Nationwide Fund Advisors now owns 10,963 shares of the medical instruments supplier’s stock valued at $107,000 after purchasing an additional 7,921 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in Sientra during the second quarter worth approximately $148,000. Dimensional Fund Advisors LP grew its position in Sientra by 23.4% during the second quarter. Dimensional Fund Advisors LP now owns 18,660 shares of the medical instruments supplier’s stock worth $181,000 after buying an additional 3,534 shares in the last quarter. Parametric Portfolio Associates LLC grew its position in Sientra by 23.0% during the second quarter. Parametric Portfolio Associates LLC now owns 20,180 shares of the medical instruments supplier’s stock worth $196,000 after buying an additional 3,770 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in Sientra by 175.2% during the third quarter. Wells Fargo & Company MN now owns 22,903 shares of the medical instruments supplier’s stock worth $353,000 after buying an additional 14,582 shares in the last quarter. 78.33% of the stock is currently owned by institutional investors.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.